SEC Form 4 · accession 0001562180-19-001664
PROGENICS PHARMACEUTICALS INC · PGNX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Bryce Tenbarge
Officer — SVP, Commercial
Period of report
Mar 1, 2019
Accepted (ET)
Mar 5, 2019 · 3:52 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000835887
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Non-Qualified Stock Option (Right to Buy)F1 | $4.52 | Mar 1, 2019 | A | 90,750 | A | — | Mar 1, 2029 | Common Stock | 90,750 | 90,750 | D |
Explanation of responses
- F13yr 33% On Vest beginning on 01-Mar-2019